Medtronic Launches the MiniMed 670G System Performance Guarantee for Payers and Employers

Medtronic (NYSE:MDT), the global leader in medical technology, announced the launch of the MiniMed(TM) 670G Performance Guarantee Program – an outcomes-based offering for payers and employers designed to mitigate costs for diabetes-related complications. With this Guarantee, Medtronic will provide flat-fee reimbursements up to $25,000 per pump over 4 years for qualifying diabetes-related inpatient hospitalization and emergency room admissions for eligible in-network patients in the United States.

As quoted in the press release:

“This new program demonstrates the strong confidence we have in our ability to deliver improved clinical outcomes with our MiniMed670G system and our commitment to value-based healthcare that not only improves outcomes but drives down the enormous burden of diabetes-related healthcare costs,” said Alejandro Galindo, president of the Advanced Insulin Management division within the Diabetes Group at Medtronic. “Medtronic is committed to working with new partners, in new ways, to create a paradigm shift in healthcare so that incentives are based on delivering better outcomes and quality of care for our patients.”

The program will provide an opportunity for Medtronic to work with payer and employer partners to identify patients who would benefit from the MiniMed 670G system, including those who may be most at-risk for diabetes-related adverse events. Given Medtronic’s comprehensive suite of products and services, including offerings like the standalone Guardian(TM) Connect continuous glucose monitoring system, the company is well positioned to identify these patients and transition them to the MiniMed 670G system, where they will be supported by our existing patient engagement program.

Click here to read the full press release.